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SOME OBSERVATIONS ON THE EFFECT OF 1-TRI-IODOTHYRONINE ON
ACNE VTJLGARIS*
RUTH K. FREINKEL, M.D.f AND ARTHUR S. LURIE, M.D.t
Although the cutaneous changes of myxedema
and Grave's disease have been well documented,
little is known of the role of the thyroid hormone
in the physiology of the pilosebaceous apparatus.
Our attention was focused on this problem by ob-
servations in five patients, aged 15 to 25, with
Grave's disease (1). In these individuals, the first
appearance of acne vulgaris or striking exacerba-
tion of a previously mild acne occurred 1 to 4
months following induction of eumetabolism by
anti-thyroid drugs. Bauer and Goodwin (2) in
1951 similarly reported the transient appearance
of acne in a series of male patients with Grave's
disease following therapy with carrier-free 1131.
In recent years, 3-5-3'l-tri-iodothyronine (T-3), a
naturally occurring thyroid hormone of greater
activity and more rapid action than thyroxine,
has become available. The ability of this hormone
to induce acute alterations in metabolism has
prompted further inquiry into the effect of thy-
roid hormone on acne. The results obtained with
T-3 during the fall and winter months of 1957—59
in eleven intensively studied female patients with
acne vulgaris form the basis of this preliminary
report.
METHODS
Patients were selected as follows: All females
with well-established moderate to severe acne who
had no clinical or laboratory evidence of abnormal
thyroid function and who were in good general
health were considered for study. They were
placed on a routine of mild topical therapy, con-
sisting of soap and water, 2 per cent sulfur and
0.5 per cent resorcinol ointment, and astringent
lotion, and observed at weekly intervals to
establish a base line. Those who adhered to the
routine and attended clinic for 4 to 9 consecutive
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weeks were then placed on 4—6 placebo tablets
daily and again seen at weekly intervals for 4 to
11 weeks. Patients who showed significant im-
provement on either topical therapy alone or
placebo tablets were excluded from further study.
Eleven subjects did not respond to these regi-
mens, but nevertheless faithfully returned for
weekly visits to the clinic. In these eleven pa-
tients, ltriiodothyronine* in doses of 100 to 150
pgm daily was substituted for placebo. Observa-
tion continued at weekly intervals for 4 to 15
weeks, after which placebo was re-exhibited for
4 weeks.
At each visit, pulse, blood pressure, and weight
were recorded and clinical evidences of metabolic
status evaluated. Basal metabolic rates were ob-
tained at suitable intervals. The skin was exam-
ined independently by two observers. Three sepa-
rate and possibly unrelated components of the
acne process on the face were selected for "quan-
titation." Oiliness was graded roughly 0 to 3-plus.
Comedones were counted and graded: 0; less than
5 (1-plus); less than 10 (2-plus); and more than
10 (3-plus). Papules and pustules were counted
and graded on the same scale as comedones. In
addition, notations were made of cysts, deep
nodules, seborrhea of the scalp, as well as texture
and color of the skin.
In evaluating the results of these estimations,
an arithmetic mean for each of these components
was derived from the numerical grades for all
observations in each of the four periods: observa-
tion, placebo, T-3, and placebo (see table). Be-
cause of the relative lack of scatter in the obser-
vations for any individual patient, significant
improvement was arbitrarily selected to be a unit
of 1.0 in the mean of either the placebo or T-3
over the observation period.
RESULTS
As can be seen from the table, no improvement
was noted during the first placebo period except
in one patient whose comedones were significantly
reduced. During the T-3 period, oiliness improved
in 7 patients, eomedones in 5, and papules and
pustules in 6. No patients showed worsening dur-
ing this time. While seborrhea of the scalp could
* l-Tri-iodothyronine (Cytomel) and identical
placebo tablets were kindly furnished by Smith,
Kline and French Laboratories.
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TABLE 1
Observations in patients with acne vulgaris during treatment with tri-iodothyronine and placebo
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Oiliness Comedones
Patient
J. F.
J. B.
J. G.
F.M.
V. M.
P. P.
A. F.
J. M.
M. G.
K. K.
T. M.
Papules and Pustnles
Ohs.
2.5
2.2
2.8
3.0
2.0
3.0
3.0
2.2
1.7
2.0
3.0
P1.
2.0
3.0
2.7
3.0
1.7
2.7
3.0
2.7
1.5
1.2
2.5
T-3
1.8
0.7
1.6
1.5
2.2
0.9
1.0
1.7
0.2
1.7
2.0
P1.
2.3
2.2
2.0
3.0
2.9
3.0
3.0
2.5
2.8
3.0
2.5
Ohs.
1.7
2.0
2.0
1.6
2.5
2.0
3.0
1.8
2.2
2.6
2.1
P1.
0.6
2.0
2.3
1.0
2.3
2.0
2.3
3.0
1.8
2.5
2.1
T-3
0.7
0.7
0
0.5
2.0
0.3
0.5
2.0
0.2
0.9
1.5
P1.
2.0
0.7
0.5
0.7
2.2
1.0
0.8
2.5
0.6
1.2
2.1
Ohs.
2.2
2.5
2.7
2.7
3.0
2.2
3.0
2.0
3.0
2.6
3.0
P1.
2.0
3.0
2.3
2.0
3.0
3.0
3.0
2.0
2.6
2.4
2.5
T-3
1.4
2.0
0
1.3
3.0
2.8
1.7
0.2
1.9
1.3
2.3
P1.
2.7
1.5
1.7
1.3
3.0
3.0
2.2
2.2
2.3
1.8
2.5
Mean.... 2.5 2.4 1.4 2.7 2.1 2.0 0.9 1.3 2.6 2.5
Ohs. = Observation period, P1. = Placebo period, T-3 = Tri-iodothyronine period. Each value is
the arithmetic mean of all observations during that period (see text).
not be readily assessed, 8 patients were able to
increase the interval between shampoos by 2 to 5
days and still maintain relatively oil-free scalp
and hair. In six patients a definite softening and
thinning of the skin, accompanied by heightened
facial color, appeared 2 to 4 weeks after institu-
tion of a minimal dose of 125 pgm of T-3. One to
two weeks after re-exhibition of the placebo pill,
there was a return of oiliness in all patients with
prior improvement; three of the six patients in
whom papules and pustules had improved showed
a flare in these lesions; no marked exacerbation of
comedones occurred in any patient.
The pre-treatment basal metabolic rate aver-
age was —12 (range —22 to —2). On the maxi-
mal dose of tri-iodothyronine, basal metabolic
rates averaged —3 (range —9 to +4). The aver-
age change was +9; only one patient failed to
get any rise, while in 4 patients the rise was +15
or greater. During the 4 to 15 week period of T-3
treatment, no significant changes in pulse rate,
blood pressure or weight were found. Side effects
were limited to mild diarrhea and nervousness in
one patient on 150 Mgm of T-3, and increased
dysmenorrhea with scanty menstrual flow in two
others.
DISCUSSION
The present report constitutes one phase of a
continuing inquiry into the intermediate metabo-
lism of skin. It has been shown that in a small
series of female patients, who were refractory to
mild topical and placebo therapy, administration
of tri-iodothyronine significantly diminished some
of the features of acne vulgaris. In the past,
thyroid hormone has been advocated for the
treatment of acne vulgaris (3, 4, 5). More re-
cently, the value of either desiccated thyroid (6)
or even T-3 (7) has been disputed. Data in sup-
port of either thesis are scanty. The data pre-
sented here do not contribute to the resolution of
this controversy and no inference that T-3 is a
useful or even desirable adjunct to the therapy of
acne can be drawn from them. The short-term
studies provide no information about the sus-
tained effectiveness of prolonged administration
of T-3. Furthermore, in the doses used T-3 effects
an acute increase in the delivery of thyroid hor-
mone to the tissues, suppresses endogenous
thyroid activity, presumably by suppression of
the thyroid-pituitary axis, and eventually lowers
the protein-bound iodine (8). It is obvious, there-
fore, that conjecture regarding the prolonged im-
plications of such therapy is hazardous.
The present data justify no conclusions about
the mode of action of T-3 in acne vulgaris: i.e.,
whether it acts on the skin per se or primarily on
the cutaneous vasculature or through other
endocrine structures.
The authors do not intend to imply that thy-
roid abnormalities are involved in the patho-
genesis of acne. However, the data may furnish
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some clues to the metabolic derangements of acne
vulgaris and justify further examination of
thyronine derivatives in which systemic and
focal metabolic effects (9) may be dissociated as
well as the effectiveness of topically applied
thyromimetic agents. Such studies are currently
in progress.
SUMMARY
A series of 11 selected, eumetabolic female pa-
tients with acne vulgaris was treated with 1-tn-
iodothyronine under controlled conditions in a
single-blind study. Administration of T-3 in doses
of 100—150 gm daily was accompanied by signifi-
cant clinical amelioration of the disease.
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